amlodipine has been researched along with nisoldipine in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 7 (25.93) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 8 (29.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herbette, LG; Mason, RP; Rhodes, DG | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Bruno-Blanch, L; Gálvez, J; García-Domenech, R | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Sun, H | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Burburan, PJ; Matubia, VN; Parkin, DW; Ramcharan, SS; Rosario, I; Shea, TA; Stockman, BJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Arena, JP; Chin, S; Kass, RS | 1 |
| Frais, MA; Jackson, N; Midtbo, KA; Reynolds, G; Sharma, S; Silke, B; Taylor, SH; Verma, SP | 1 |
| Gilar, M; Tesarová, E; Uhrová, M | 1 |
| Curry, P; Dens, J; Hagel, H; Melcher, A | 1 |
| Furberg, CD; Pahor, M; Psaty, BM | 1 |
| Pahor, M; Tatti, P | 1 |
| Ellsworth, A; Fink, KS | 1 |
| Mak, IT; Weglicki, WB; Zhang, J | 1 |
| Ciuryla, V; Enzmann, G; Johnson, R; Pershadsingh, HA; Reisin, E; Whitcomb, C | 1 |
| Hilleman, DE; Lenz, TL; Wurdeman, RL | 1 |
| Bittar, N; Cooper-DeHoff, RM; Hutchinson, HG; Koren, M; Michelson, EL; Minkwitz, MC; Pepine, CJ; Thadani, U; Weiss, RJ | 1 |
| Dens, J; Desmet, W; Piessens, J | 1 |
| Ferdinand, K; Noveck, RJ; Saunders, E; White, WB | 1 |
4 review(s) available for amlodipine and nisoldipine
| Article | Year |
|---|---|
Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
Topics: Cell Membrane; Chemical Phenomena; Chemistry, Physical; Kinetics; Lipid Bilayers; Membrane Lipids; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Structure-Activity Relationship | 1991 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Nisoldipine CC: clinical experience in ischaemic heart disease.
Topics: Amlodipine; Calcium Channel Blockers; Delayed-Action Preparations; Diltiazem; Double-Blind Method; Humans; Myocardial Ischemia; Nisoldipine; Randomized Controlled Trials as Topic | 1997 |
An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty.
Topics: Amlodipine; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Confidence Intervals; Coronary Disease; Coronary Restenosis; Humans; Incidence; Nisoldipine; Odds Ratio; Randomized Controlled Trials as Topic | 2003 |
6 trial(s) available for amlodipine and nisoldipine
| Article | Year |
|---|---|
Comparative hemodynamic dose-response effects of five slow calcium channel-blocking agents in coronary artery disease.
Topics: Amlodipine; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Diltiazem; Dose-Response Relationship, Drug; Female; Hemodynamics; Humans; Male; Middle Aged; Nicardipine; Nifedipine; Nisoldipine; Prospective Studies; Random Allocation; Verapamil | 1987 |
The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) and combination therapies.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Drug Combinations; Enalapril; Follow-Up Studies; Fosinopril; Heart Diseases; Humans; Hypertension; Nisoldipine; Prospective Studies; Reproducibility of Results; Risk Factors; Treatment Outcome | 1999 |
A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Delayed-Action Preparations; Double-Blind Method; Drug Costs; Female; Humans; Hypertension; Least-Squares Analysis; Male; Middle Aged; Nisoldipine; Single-Blind Method; Therapeutic Equivalency; Treatment Outcome | 2000 |
Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cross-Over Studies; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nisoldipine; Patient Compliance; Time Factors | 2001 |
Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Delayed-Action Preparations; Double-Blind Method; Exercise Test; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Nisoldipine | 2003 |
Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Circadian Rhythm; Diastole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Female; Heart Rate; Humans; Hypertension; Incidence; Male; Middle Aged; Nisoldipine; Prospective Studies; Systole; Treatment Outcome; United States; Vasodilator Agents | 2003 |
17 other study(ies) available for amlodipine and nisoldipine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
Topics: Anticonvulsants; Computer Simulation; Databases, Factual; Discriminant Analysis; Drug Design; Molecular Structure; Quantitative Structure-Activity Relationship | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
Topics: Carboxylic Acids; Cytochrome P-450 Enzyme System; Esters; Humans; Hydrolysis; Microsomes; Models, Molecular; Molecular Structure; Prodrugs; Quantum Theory; Signal Transduction | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Molecular Structure; N-Glycosyl Hydrolases; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Structure-Activity Relationship; Trichomonas vaginalis | 2014 |
Block of L-type calcium channels by charged dihydropyridines. Sensitivity to side of application and calcium.
Topics: Amlodipine; Animals; Calcium; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels; Cell Membrane; Chemical Phenomena; Chemistry, Physical; Diffusion; Dihydropyridines; Guinea Pigs; Heart; In Vitro Techniques; Membrane Potentials; Myocardium; Nifedipine; Nisoldipine; Receptors, Nicotinic | 1991 |
Enantiomer separation of dihydropyridine calcium antagonists with cyclodextrins as chiral selectors: structural correlation.
Topics: Amlodipine; Buffers; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Cyclodextrins; Dihydropyridines; Electrolytes; Electrophoresis, Capillary; Isradipine; Microspheres; Molecular Conformation; Nimodipine; Nisoldipine; Nitrendipine; Sodium Dodecyl Sulfate; Solvents; Stereoisomerism; Surface-Active Agents | 1996 |
Treatment of hypertensive patients with diabetes.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Case-Control Studies; Cohort Studies; Diabetes Complications; Enalapril; Fosinopril; Humans; Hydrochlorothiazide; Hypertension; Isradipine; Nisoldipine; Randomized Controlled Trials as Topic | 1998 |
Antihypertensive treatment and CHD in the elderly.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Complications; Double-Blind Method; Felodipine; Fosinopril; Humans; Hypertension; Myocardial Infarction; Nisoldipine; Nitrendipine; Randomized Controlled Trials as Topic | 1999 |
Cytoprotective properties of nisoldipine and amlodipine against oxidative endothelial cell injury.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cattle; Cells, Cultured; Endothelium, Vascular; Lipid Peroxidation; Nisoldipine; Oxidative Stress | 2000 |